Abstract:Aim A standard strain of HSV-1 (strain F) and Acyclovir(ACV)-resistant strains HSV-1 (strain 153/BLUE/106) were used to investigate the antiviral activity of Cyanovirin-N (CVN) and its derivatives (LCVN, mPEG10K-ALD-LCVN). Moreover, antiviral mode and mechanism of antiviral of LCVN was studied. Experimental HSV-1 (strain F) was maintained in our laboratory and propagated in Vero cells. HSV-1 (strain 153/BLUE/106) resistant strains were isolated from children with herpes labial in Guangzhou Children's Hospital. Purified recombinant CVN, LCVN and thePEGylated product 10 K PEGALD-LCVN were prepared in-house by a processmodified as reported previously.Vero cells were maintained in our laboratory and grown in DMEM medium supplemented with 10% FBS, 100 U/mL penicillin and 100 microg/mL streptomycin. Cytopathic effect (CPE) and MTT assays were used to evaluate the effect of CVN and itsderivatives on HSV-1 in Vero cells. The number of copies of HSV-DNA was detected by real-time fluorescence quantitative PCR (FQ-PCR). Result and discussion The results showed that CVN, LCVN and mPEG10K-ALD-LCVN had a low cytotoxicity on Vero cells with a median lethal concentration (TC50) of 1.456±0.340 microM1.747±0.097 microM 9.48±1.403 microM respectively; LCVN and mPEG10K-ALD-LCVN completely inhibit viral infection at the concentration of 0.1 microM and 2 microM respectively. The antiviral activity of CVN, LCVN and mPEG10K-ALD-LCVN were stronger than acyclovir significantly at Low micromolar. The effect of inhibiting viral attachment and penetration of LCVN were modest whereas thetreatment after virus infection was noticeable. The results showed that LCVN cannot inhibit the transcription of immediate early gene (UL54), but it can significantly inhibit transcription of the late gene (UL27), thereby inhibiting viral proliferation. Conclusion It is easy for the nucleoside analogue to develop drug-resistant strains following long period of treatment, whereas LCVN can inhibit HSV-1 and its ACV-resistant strains though multiple mechanisms. Thus, LCVN is an effective drug for HSV-1 and its ACV-resistant strains.

Linker-Extended Native Cyanovirin-N Facilitates PEGylation and Potently Inhibits HIV-1 by Targeting the Glycan Ligand

Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1

Preparation of Monopegylated Cyanovirin-N's Derivative and Its Anti-Influenza A Virus Bioactivity in Vitro and in Vivo.

Enfuvirtide−PEG Conjugate: A Potent HIV Fusion Inhibitor with Improved Pharmacokinetic Properties

[Expression, purification and activity determination of cyanovirin-N].

A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor Ccr5 Heterodimer: Binding Affinity Versus Functional Activities

Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells

Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses

Antiviral Activity and Its Mechanism of LCVN Against HSV-1 Acyclovir-resistant Strains

An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides.

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies

Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.

Synthesis, Biological Evaluation and Molecular Docking Study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide Derivatives As Potent HIV-1 Vif Antagonists.

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.

Long-Acting HIV-1 Fusion Inhibitory Peptides and Their Mechanisms of Action

Engineering recombinantly expressed lectin-based antiviral agents

The Antiviral Protein Cyanovirin-N: the Current State of Its Production and Applications

Improving Anti-HIV activity and pharmacokinetics of enfuvirtide (T20) by modification with oligomannose

Progress in Research of the Anti-Hiv Inhibitor Cyanovirin-N

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane